[go: up one dir, main page]

CA2029420A1 - Compositions pharmaceutiques et methodes permettant d'inhiber la reaction de maillard - Google Patents

Compositions pharmaceutiques et methodes permettant d'inhiber la reaction de maillard

Info

Publication number
CA2029420A1
CA2029420A1 CA2029420A CA2029420A CA2029420A1 CA 2029420 A1 CA2029420 A1 CA 2029420A1 CA 2029420 A CA2029420 A CA 2029420A CA 2029420 A CA2029420 A CA 2029420A CA 2029420 A1 CA2029420 A1 CA 2029420A1
Authority
CA
Canada
Prior art keywords
reaction
methods
pharmaceutical compositions
maillard
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2029420A
Other languages
English (en)
Other versions
CA2029420C (fr
Inventor
Jun Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of CA2029420A1 publication Critical patent/CA2029420A1/fr
Application granted granted Critical
Publication of CA2029420C publication Critical patent/CA2029420C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
CA002029420A 1989-11-21 1990-11-07 Compositions pharmaceutiques et methodes permettant d'inhiber la reaction de maillard Expired - Fee Related CA2029420C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1304479A JP2854631B2 (ja) 1989-11-21 1989-11-21 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤
JP304479/1989 1989-11-21

Publications (2)

Publication Number Publication Date
CA2029420A1 true CA2029420A1 (fr) 1991-05-22
CA2029420C CA2029420C (fr) 2000-09-19

Family

ID=17933520

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002029420A Expired - Fee Related CA2029420C (fr) 1989-11-21 1990-11-07 Compositions pharmaceutiques et methodes permettant d'inhiber la reaction de maillard

Country Status (8)

Country Link
EP (1) EP0430045B1 (fr)
JP (1) JP2854631B2 (fr)
KR (1) KR910009272A (fr)
AT (1) ATE121939T1 (fr)
CA (1) CA2029420C (fr)
DE (1) DE69019111T2 (fr)
DK (1) DK0430045T3 (fr)
ES (1) ES2071725T3 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05286848A (ja) * 1992-04-10 1993-11-02 Senju Pharmaceut Co Ltd 浴用剤
DK0679088T3 (da) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
CA2129509A1 (fr) * 1993-09-10 1995-03-11 Kazumi Ogata Composition pharmaceutique pour les troubles renaux et solution de dialyse pour l'hemodialyse extracorporelle
CA2183577C (fr) 1994-03-07 2007-10-30 John S. Patton Methodes et compositions pour l'administration pulmonaire d'insuline
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
JP3362501B2 (ja) * 1994-04-28 2003-01-07 千寿製薬株式会社 角膜障害治療剤
JP3396953B2 (ja) * 1994-05-10 2003-04-14 千寿製薬株式会社 網膜疾患予防・治療剤
JPH07330501A (ja) 1994-06-14 1995-12-19 Senju Pharmaceut Co Ltd 肝保存剤および肝保存方法
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
CA2152693A1 (fr) * 1994-08-05 1996-02-06 Kazumi Ogata Composition therapeutique pour la pancreatite
US5795912A (en) * 1995-04-26 1998-08-18 Senju Pharmaceutical, Co., Ltd. Therapeutic composition for corneal impairment
CA2179940A1 (fr) 1995-07-18 1997-01-19 Kazumi Ogata Composition antiallergique renfermant un compose de type diester phosphorique
CA2186654A1 (fr) * 1995-10-13 1997-04-14 Masayuki Nakamura Diester phosphorique
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
WO1999039716A1 (fr) * 1998-02-03 1999-08-12 Senju Pharmaceutical Co., Ltd. Substances preventives et medicaments destines aux maladies neurodegeneratives
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
JP4745608B2 (ja) 2001-07-27 2011-08-10 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 電子伝達剤のリン酸誘導体を用いた皮膚治療
AUPR684801A0 (en) * 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
MXPA04001779A (es) * 2001-09-26 2004-05-31 Vital Health Sciences Pty Ltd Modulacion de almacenamiento de vitamina.
WO2003053411A1 (fr) 2001-12-19 2003-07-03 Nektar Therapeutics Administration pulmonaire d'aminoglycosides
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
EP1720551B9 (fr) 2004-03-03 2011-09-21 Vital Health Sciences Pty Ltd. Formulations alcaloides
JP2008531603A (ja) * 2005-03-03 2008-08-14 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 脂質低下特性を有する化合物
WO2006133506A1 (fr) 2005-06-17 2006-12-21 Vital Health Sciences Pty Ltd Charge comprenant un ou plusieurs dérivés de di- et/ou monophosphate d’agent de transfert d’électrons ou des complexes de ceux-ci
ES2999020T3 (en) 2010-02-05 2025-02-24 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
RU2553350C2 (ru) 2010-03-30 2015-06-10 Фосфейдженикс Лимитед Трансдермальные пластыри
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
CN104297412B (zh) * 2014-10-17 2015-12-02 徐州工程学院 一种蛋白粉新鲜度的测定方法
CN114712308A (zh) 2015-12-09 2022-07-08 磷肌酸有限公司 药物制剂
US20190330260A1 (en) 2016-12-21 2019-10-31 Avecho Biotechnology Limited Process

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59219295A (ja) * 1983-05-30 1984-12-10 Senjiyu Seiyaku Kk リン酸ジエステルまたはその塩およびそれらの製造法
JPS62205091A (ja) * 1986-03-04 1987-09-09 Senjiyu Seiyaku Kk 新規なリン酸ジエステルならびにその塩、その製造法およびそれを含有する製剤
JP2546687B2 (ja) * 1987-09-11 1996-10-23 千寿製薬株式会社 リン酸ジエステルまたはその塩からなる抗酸化剤
PH25859A (en) * 1988-01-11 1991-12-02 Takeda Chemical Industries Ltd Composition for treatment of ischemic disorder

Also Published As

Publication number Publication date
KR910009272A (ko) 1991-06-28
JPH03161444A (ja) 1991-07-11
EP0430045A2 (fr) 1991-06-05
DK0430045T3 (da) 1995-07-17
ES2071725T3 (es) 1995-07-01
DE69019111D1 (de) 1995-06-08
ATE121939T1 (de) 1995-05-15
EP0430045A3 (en) 1991-11-06
EP0430045B1 (fr) 1995-05-03
DE69019111T2 (de) 1995-08-31
CA2029420C (fr) 2000-09-19
JP2854631B2 (ja) 1999-02-03

Similar Documents

Publication Publication Date Title
CA2029420A1 (fr) Compositions pharmaceutiques et methodes permettant d'inhiber la reaction de maillard
AU599792B2 (en) Anti-parkinsonian indolone derivatives
AU2246292A (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
EP0433679A3 (en) Pharmaceutical compositions for inhibition of maillard's reaction
GR3018387T3 (en) Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them.
AU581442B2 (en) 2-substituted-1, 3-propylidenediphosphonate derivatives, the process for their preparation and pharmaceutical compositions containing them
AU1302388A (en) Method of treating anxiety with tetrahydrobenz(c,d)indole-6- carboxamides
CA2014771A1 (fr) 5,11-dihydro-6h-dipyrido[3,2-b:2'3'-e][1,4]diazepine-6-ones et leur utilisation pour la prevention ou le traitement du sida
AU6948091A (en) Thiazolidine derivatives having anti-hypertensive activity and their therapeutic use
EP0342587A3 (fr) Thiénotriazolodiazépines et leur applications pharmaceutiques
EP0270046A3 (en) Pharmaceutical composition for treatment of cataract
AU3126289A (en) 4,5,6,7-tetrahydro isothiazolo (4,5-c) pyridine derivatives
HUT46214A (en) Process for producing medical preparation suitable for treatment of peptic ulcer
AU4610689A (en) Pyridine-3-peroxycarboxylic acid monopersulfate
GB8608893D0 (en) D-nor-7-ergoline derivatives
SG4595G (en) Use of 2-oxo-imidazolidine derivatives in the prophylaxis and treatment of heart failure
EP0272849A3 (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases
AU2013888A (en) Uricosuric composition
JPS6434920A (en) Therapy for mycobacterium abium intracellular complex infection

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed